Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.

Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF.

Diabetes. 2014 Jul;63(7):2394-401. doi: 10.2337/db13-1654. Epub 2014 Feb 28.

2.

Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes.

Tremblay AJ, Lamarche B, Kelly I, Charest A, Lépine MC, Droit A, Couture P.

Diabetes Obes Metab. 2014 Dec;16(12):1223-9. doi: 10.1111/dom.12359. Epub 2014 Aug 19.

PMID:
25059982
3.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.

PMID:
16912128
4.

Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.

Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A, Ahrén B.

Diabetes Obes Metab. 2013 Jun;15(6):531-7. doi: 10.1111/dom.12062. Epub 2013 Feb 7.

PMID:
23331498
5.

Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.

Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1513-9. doi: 10.1161/ATVBAHA.112.246207. Epub 2012 Apr 5.

6.
7.

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P.

Diabetes Obes Metab. 2011 Apr;13(4):366-73. doi: 10.1111/j.1463-1326.2011.01362.x.

PMID:
21226820
8.

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A.

Diabetes Care. 2010 Jul;33(7):1607-9. doi: 10.2337/dc10-0187. Epub 2010 Mar 31.

9.

Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects.

Huang CL, Hsu CH, Huang KC, Su HY, Weng SF.

Pharmacology. 2010;85(3):131-5. doi: 10.1159/000280583. Epub 2010 Feb 9.

PMID:
20145424
10.

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.

PMID:
17559733
11.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
12.

Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.

Imai C, Saito M, Mochizuki K, Fuchigami M, Goda T, Osonoi T.

Metabolism. 2014 Jun;63(6):746-53. doi: 10.1016/j.metabol.2013.12.014. Epub 2014 Jan 7.

PMID:
24559582
13.

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J.

Endocr J. 2010;57(5):383-94. Epub 2010 Mar 24.

14.

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.

Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2013 Mar;15(3):237-40. doi: 10.1089/dia.2012.0214. Epub 2013 Feb 12.

PMID:
23402316
15.

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S.

Diabetes Obes Metab. 2012 Sep;14(9):795-802. doi: 10.1111/j.1463-1326.2012.01600.x. Epub 2012 Apr 18.

PMID:
22443183
16.

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK.

Diabet Med. 2011 Oct;28(10):1176-81. doi: 10.1111/j.1464-5491.2011.03331.x.

PMID:
21923696
17.

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

Bailey CJ, Green BD, Flatt PR.

Expert Opin Investig Drugs. 2010 Aug;19(8):1017-25. doi: 10.1517/13543784.2010.505235. Review.

PMID:
20629618
18.

The amino acid response to a mixed meal in patients with type 2 diabetes: effect of sitagliptin treatment.

Muscelli E, Frascerra S, Casolaro A, Baldi S, Mari A, Gall W, Cobb J, Ferrannini E.

Diabetes Obes Metab. 2014 Nov;16(11):1140-7. doi: 10.1111/dom.12350. Epub 2014 Aug 4.

PMID:
25040945
19.

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.

PMID:
18476982
20.

Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study.

Price JD, Linder G, Li WP, Zimmermann B, Rother KI, Malek R, Alattar M, Tarbell KV.

Clin Exp Immunol. 2013 Oct;174(1):120-8. doi: 10.1111/cei.12144.

Supplemental Content

Support Center